MannKind Corporation (MNKD) Announces FDA Acknowledgement of Resubmission of New Drug Application for AFREZZA
10/30/2013 7:39:42 AM
VALENCIA, Calif.--(BUSINESS WIRE)--MannKind Corporation (Nasdaq: MNKD) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of a New Drug Application (NDA) for AFREZZA® (insulin human [rDNA origin]) Inhalation Powder. The FDA considered the updated NDA to be a complete class 2 response to its Complete Response Letter issued in January 2011 and assigned a user fee goal date of April 15, 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by